Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris
PR Newswire —
Acne vulgaris affects an estimated 650 million people worldwide with a significant impact on quality of life, mental well-being, and self-esteem. AT-004 targets a novel, TNF-α-modulating anti-inflammatory pathway in the skin, with relevance across multiple inflammatory dermatologic...